Oncology

News

BMS study of Opdualag in adjuvant melanoma ends in failure

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.

News

Merck confirms its interest in buying SpringWorks

Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.

News

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.

News

Woman attended by female radiologist having a mammogram

NHS trial puts AI for breast cancer screening under scrutiny

Nearly 700,000 women will be recruited into an NHS trial of AI tools for breast cancer screening, in the hope of relieving pressure on radiologists.

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

BMS study of Opdualag in adjuvant melanoma ends in failure

Merck confirms its interest in buying SpringWorks

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

NHS trial puts AI for breast cancer screening under scrutiny

Pfizer builds on Braftovi bowel cancer OK with survival data

Boost to Enhertu's prospects as FDA clears Roche diagnostic

AZ's ATR inhibitor ceralasertib flunks lung cancer test

How to meet your physicians where they are online

Oncology

Editor's Picks